Samsung Biologics Expands Peptide CDMO Power with $1.46B PolyPeptide Deal

Peptide therapeutics represent one of the fastest-growing segments in drug development, with blockbusters like semaglutide demonstrating the modality’s potential. Samsung Biologics’ move to acquire PolyPeptide is a direct shot at dominating this space. By integrating peptide API production with its world-class biologics capability, Samsung creates a CDMO that can handle everything from monoclonal antibodies to peptide conjugates, a strategic leap that could reshape outsourcing patterns across the industry.

Samsung Biologics' announcement of an all-cash public tender offer for PolyPeptide Group AG represents a strategic acceleration of its multi-modality CDMO ambitions. The offer of CHF 44.31 per share, valuing PolyPeptide at approximately CHF 1.46 billion, signals Samsung's determination to expand beyond large-molecule biologics into the high-growth peptide API market. The transaction has immediate strong support: PolyPeptide's board, acting through independent members, unanimously recommends the deal, and the largest shareholder, commanding approximately 55.65% of outstanding shares, has provided an irrevocable tender undertaking. This essentially assures the deal's completion barring unexpected regulatory hurdles or a competing superior bid.

“

Samsung Biologics' announcement of an all-cash public tender offer for PolyPeptide Group AG represents a strategic acceleration of its multi-modality CDMO ambitions.

PolyPeptide is a global peptide CDMO with established facilities across the U.S., Europe, and India. Peptides are a distinct and increasingly vital class of active pharmaceutical ingredients, with applications spanning hormone therapies (e.g., GLP-1 agonists like semaglutide), antibiotics, immuno-oncology, and other emerging biotherapeutics. The peptide therapeutics market is projected to grow at a compound annual rate exceeding 8%, driven by advances in synthesis and delivery technologies. By acquiring PolyPeptide, Samsung Biologics directly addresses a modality gap in its portfolio. Samsung has historically excelled in mammalian cell culture and microbial fermentation for monoclonal antibodies, vaccines, and other biologics. Adding peptide chemistry creates a truly integrated CDMO capable of serving clients across the full spectrum of biological and synthetic molecules, a one-stop-shop that few competitors can offer.

From a competitive standpoint, the acquisition positions Samsung Biologics more squarely against established peptide-focused CDMOs like Bachem, CordenPharma, and PolyPeptide itself, as well as large diversified players such as Lonza and Thermo Fisher, which already span multiple modalities. The move also aligns with an industry trend where large CDMOs are consolidating to offer end-to-end services, shortening development timelines and reducing supply chain complexity for pharmaceutical clients. Samsung's footprint in key geographies will expand meaningfully, adding production sites in Europe and India, which are critical for serving both Western and emerging market demand. This is particularly important as post-pandemic supply chain resilience remains a priority for drug sponsors.

The tender offer structure—all-cash, directly targeting 100% of PolyPeptide's shares—suggests a swift execution path. Samsung Biologics had sufficient cash reserves and strong credit to fund the CHF 1.46 billion deal without raising equity, although the exact financing details were not disclosed in the announcement. The deal is subject to typical conditions, including regulatory clearances in relevant jurisdictions. Given that PolyPeptide's operations do not appear to raise significant national security or antitrust concerns, approval is expected to be routine. The irrevocable commitment from the dominant shareholder further reduces uncertainty.